Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular

Set Alert for Cardiovascular

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Research & Development Clinical Trials

Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success

Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.

Clinical Trials Cardiovascular

Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping

Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.

Cardiovascular Clinical Trials

BMS Advances Cardiovascular Growth Plans With Milvexian, Camzyos Milestones

Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.

Clinical Trials Strategy

Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

Phase III studies testing the oral PCSK9 inhibitor MK-0616 for high cholesterol will begin in the second half of the year and include a broad program enrolling primary and secondary prevention patients.

Cardiovascular Business Strategies

Esperion Preps Nexletol/Nexlizet To Be ‘Clear Next Step’ After Statins

The company plans to ramp up its commercial infrastructure later this year, ahead of a labeling update based on positive cardiovascular outcomes trial data.

Cardiovascular Clinical Trials

Cytokinetics To Move On From Omecamtiv After FDA’s Complete Response Letter

Company said it will not conduct the additional Phase III trial recommended by the US FDA. Instead, it will focus on its cardiac myosin inhibitor, aficamten, and look for partners to take omecamtiv forward.

Drug Approval Standards Clinical Trials

Theravance Dumps JAK Inhibitor Program, Focuses On Neurogenic Orthostatic Hypotension

Ampreloxetine failed in a Phase III trial in 2021, but the company will start a registrational trial by the end of Q1 for the drug in the multiple system atrophy population, where it has shown efficacy.

Sales & Earnings Cardiovascular

European Pharma 2023: A Rocky Year For Roche But Novo Is Rising Fast

Roche remains the European sector’s biggest company despite a wobble in 2022, but Novo Nordisk’s spectacular growth has seen it overtake AstraZeneca and Novartis in market cap terms.

Cancer Cardiovascular

How HALO Slip Proved Costly For CinCor In AstraZeneca Talks

Hindsight is a wonderful thing but the saga of AstraZeneca's acquisition of CinCor is an eye-opener as SEC filings reveal that a $60 per share offer was rejected in September before a $26 bid won the day earlier this month.  

M & A Cardiovascular

As Merck Diversifies Beyond Keytruda, It Will Lean On Its Oncology Leadership Position

Merck Research Laboratories president Dean Li said there is no ideal product mix for the company, but noted cancer drugs will remain a priority given the groundwork Keytruda laid for Merck in oncology.

Growth Strategy

NewAmsterdam Takes Another Step Toward CETP Inhibitor Success

Positive Phase II data indicate that obicetrapib, a cholesterol-lowering drug licensed from Amgen, could succeed where prior drugs in the class have consistently failed for more than a decade.

Clinical Trials Business Strategies
See All
UsernamePublicRestriction

Register